# US 2006/0153862 A1 · Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153862 A1
- Document ID: US20060153862A1
- Status: Published application
- Kind: A1
- Application number: 11/302,285
- Filed: 2005-12-14
- Published: 2006-07-13
- Earliest claimed: 1998-07-15
- Assignees: Neovacs
- Inventors: Daniel Zagury; Jean-Francois Zagury
- Web page: https://patentgrep.com/patent/US20060153862A1

## CPC

- C07K 14/005: from viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/084: Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
- C07K 16/112: Retroviridae (F), e.g. leukemia viruses
- C07K 16/1147: {Regulatory proteins, e.g. trans-activator of transcription [TAT], rev or vacuolar protein targeting [VPT]}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K 2319/21: containing a His-tag
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C12N 2710/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/14022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

An immumogenic polypeptide for inducing antibodies that neutralize the immunosuppressive and/or angiogenic activity of an E7 protein from Papillomavirus, wherein said immunogenic polypeptide consists of an E7 protein from Papillomavirus that has been inactivated so as to eliminate at least 70% of the immunosuppressive and/or angiogenic activity of the non-inactivated E7 protein. The inactivation is effected by physical and/or chemical treatments and/or by modification of the amino acid sequence of the polypeptide.

## Claims

### Claim 1

An immunogenic polypeptide for inducing antibodies that neutralize the immunosuppressive and/or angiogenic activity of an E7 protein from Papillomavirus, wherein said immunogenic polypeptide consists of an E7 protein from Papillomavirus that has been inactivated, so as to eliminate at least 70% of the immunosuppressive and/or angiogenic activity of the non-inactivated E7 protein, by physical and/or chemical treatment, and/or by modification of the amino acid sequence thereof.

### Claim 2 (depends on 1)

The immunogenic polypeptide according to claim 1, consisting of an E7 protein that has been inactivated by a physical treatment selected from the group consisting of heat treatment, UV irradiation, X-ray irradiation, and contact with an atmosphere rich in O2.

### Claim 3 (depends on 1)

The immunogenic polypeptide according to claim 1, consisting of an E7 protein that has been inactivated by a chemical treatment selected from the group consisting of treatment carried out with the aid of a coupling agent, treatment carried out with the aid of a carrier protein activated by pre-treatment with a dialdehyde, treatment with a monoaldehyde, carboxymethylation, carboxyamidation, maleimidation, and galenical presentation with an oily liquid.

### Claim 4 (depends on 3)

An immunogenic polypeptide in accordance with claim 3, wherein the chemical treatment is treatment carried out with the aid of a coupling agent.

### Claim 5 (depends on 4)

An immunogenic polypeptide in accordance with claim 4, wherein said coupling agent is a dialdehyde.

### Claim 6 (depends on 5)

An immunogenic polypeptide in accordance with claim 5, wherein said dialdehyde is glutaraldehyde.

### Claim 7 (depends on 3)

An Immunogenic polypeptide in accordance with claim 3, wherein the chemical treatment is treatment with a monoaldehyde.

### Claim 8 (depends on 7)

An immunogenic polypeptide in accordance with claim 7, wherein said monoaldehyde is formaldehyde.

### Claim 9 (depends on 3)

An immunogenic polypeptide in accordance with claim 3, wherein the chemical treatment is carboxyamidation.

### Claim 10 (depends on 3)

An Immunogenic polypeptide in accordance with claim 3, wherein the chemical treatment is carboxymethylation.

### Claim 11 (depends on 3)

An immunogenic polypeptide in accordance with claim 3, wherein the chemical treatment is maleimidation.

### Claim 12 (depends on 3)

An immunogenic polypeptide in accordance with claim 3, wherein the chemical treatment is galenical presentation with an oily liquid.

### Claim 13 (depends on 1)

An immunogenic polypeptide in accordance with claim 1, that has been inactivated by modification of the amino acid sequence of an E7 protein from Papillomavirus, said modification being insertions, deletions or substitutions of residues in the amino acid sequence of said E7 protein.

### Claim 14 (depends on 1)

An immunogenic polypeptide in accordance with claim 1, that has been inactivated by modification of the amino acid sequence of an E7 protein from Papillomavirus to obtain a fragment of said E7 protein.

### Claim 15 (depends on 1)

An immunogenic polypeptide in accordance with claim 1, that has been inactivated by carboxyamidating an E7 protein from Papillomavirus or a fragment thereof, which fragment is from 8 to 110 amino acid residues in length such that the carboxyamidated form thereof is capable of raising antibodies that neutralize the immunosuppressive and/or angiogenic activity of said E7 protein.

### Claim 16 (depends on 1)

An Immunogenic polypeptide according to claim 1, originating from an E7 protein from Papillomavirus selected from the group consisting of HPV strain 16 and HPV strain 18.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising an immunogenic polypeptide according to claim 1.

### Claim 18 (depends on 1)

An immunogenic composition comprising an immunogenic polypeptide according to claim 1, together with at least one adjuvant.

### Claim 19 (depends on 1)

A vaccine composition comprising an immunogenic polypeptide according to claim 1, together with at least one adjuvant.
